摘要
目的:观察强化抗血小板治疗对平板运动试验中ST段抬高患者的临床疗效。方法:平板运动试验ST段抬高患者65例按就诊顺序双盲随机分为受试组(n=33)和对照组(n=32),受试组在对照组给予阿司匹林、氯吡格雷、肝素等基础治疗上加用血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂(盐酸替罗非班),观察2组临床疗效及不良反应发生情况。结果:受试组心绞痛的发作次数及发作平均持续时间,较对照组明显降低(P<0.05);疗程结束后行选择性冠状动脉造影术(SCA)检查,心肌梗死溶栓试验(TIMI)血流分级达3级比率高于对照组(P<0.05);主要终点事件有下降趋势;未出现严重不良反应。结论:强化抗血小板治疗,可改善平板运动试验ST段抬高患者的临床症状和近期预后,未发现严重出血等并发症。
Objective： To evaluate the clinical effects and safety of aggressive antiplatelet therapy in the patients with ST segment elevation during ECG treadmill exercise test. Method：65 patients with ST segment elevation during ECG treadmill exercise test were randomized to treat with tirofiban plus heparin on with heparin as a control, all patients received aspirin and clopidogrel if there were no contraindication. Observation： changing of angina during medication, the TIMI flow in Selective Coronary Angiography（SCA） at the end of the treatment, the 4.5 clay and 30 clay primary composite endpoint （persistent myocardial ischaemic, new onset myocardial infarction and death） and adverse drug effect. Result： Compared with control group, tirofitan group had a significant decrease in frequencies （form 8.26 ± 3.51 to 0.96 ± 1.24, P 〈 0.05） and average duration （form 36.44 ± 13.57 to 5.65 ± 2.72, P 〈 0.05） of angina, a greater percentage of TIMI 3 flow in SCA（45.5% vs 15.6%, P 〈 0.05）, and reduced tendency of primary end point events. There was no significant adverse drug effect in two groups. Conclusion： Aggressive antiplatelet therapy is effective and safe for patients with ST segment elevation during ECG treadmill exercise test.
出处
《心肺血管病杂志》
CAS
2008年第1期21-23,共3页
Journal of Cardiovascular and Pulmonary Diseases
